Akili (Nasdaq:AKLI) - Aandelenkoers, Nieuws & Analyse

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

AKLI Overzicht aandelen

A digital medicine company, develops cognitive treatments through game-changing technologies.

AKLI fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 44.19% per jaar groeien

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft geen zinvolle omzet ( $2M )

Heeft geen betekenisvolle marktkapitalisatie ( $34M )

Akili, Inc. Concurrenten

iCAD

NasdaqCM:ICAD

US$50.1m

JRSIS Health Care

OTCPK:JRSS

US$26.1m

DarioHealth

NasdaqCM:DRIO

US$29.8m

CareCloud

NasdaqGM:CCLD

US$37.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Akili
Historische aandelenkoersen
Huidige aandelenkoers	US$0.43
52 Week Hoogtepunt	US$1.25
52 Week Laag	US$0.19
Bèta	1.72
11 maand verandering	2.71%
3 maanden verandering	71.16%
1 Jaar Verandering	-62.76%
33 jaar verandering	-95.70%
5 jaar verandering	n/a
Verandering sinds IPO	-95.73%

Recent nieuws en updates

Recent updates

Akili surges 21% as Singapore investment firms take joint stake

Aug 26

Rendement voor aandeelhouders

	AKLI	US Healthcare Services	US Markt
7D	-0.6%	-0.3%	0.5%
1Y	-62.8%	8.8%	36.8%

Rendement versus industrie: AKLI presteerde slechter dan de US Healthcare Services -sector, die het afgelopen jaar een rendement van 8.8 % opleverde.

Rendement versus markt: AKLI presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 36.8 % opleverde.

Prijsvolatiliteit

Is AKLI's price volatile compared to industry and market?
AKLI volatility
AKLI Average Weekly Movement	21.3%
Healthcare Services Industry Average Movement	10.3%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.0%

Stabiele aandelenkoers: De aandelenkoers van AKLI is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 21% ) van AKLI is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2011	68	Matt Franklin	www.akiliinteractive.com

Akili, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Akili zich tot de beurswaarde?
AKLI fundamentele statistieken
Marktkapitalisatie	US$34.01m
Inkomsten(TTM)	-US$48.54m
Inkomsten(TTM)	US$1.95m

17.5x

P/S-verhouding

-0.7x

Koers/Winstverhouding

Is AKLI overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AKLI resultatenrekening (TTM)
Inkomsten	US$1.95m
Kosten van inkomsten	US$855.00k
Brutowinst	US$1.09m
Overige uitgaven	US$49.64m
Inkomsten	-US$48.54m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.62
Brutomarge	56.11%
Nettowinstmarge	-2,492.04%
Schuld/Eigen Vermogen Verhouding	22.5%

Hoe presteerde AKLI op de lange termijn?

Bekijk historische prestaties en vergelijking

This company has been acquired

AKLI Overzicht aandelen

Beloningen

Risicoanalyse

Akili, Inc. Concurrenten

NasdaqCM:ICAD

US$50.1m

OTCPK:JRSS

US$26.1m

NasdaqCM:DRIO

US$29.8m

NasdaqGM:CCLD

US$37.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Akili, Inc.(NasdaqCM:AKLI) dropped from NASDAQ Composite Index

Akili to Delist from Nasdaq

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with AdHD Through a Video Game

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Akili, Inc. to Report Q1, 2024 Results on May 14, 2024

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product

Recent updates

Akili, Inc.(NasdaqCM:AKLI) dropped from NASDAQ Composite Index

Akili to Delist from Nasdaq

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with AdHD Through a Video Game

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Akili, Inc. to Report Q1, 2024 Results on May 14, 2024

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product

Akili, Inc. Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan

New major risk - Share price stability

Akili, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board

Price target increased by 25% to US$5.00

Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Akili Receives Non-Compliance Notice from Nasdaq

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Releases Results from A New Study Examining the Way in Which Adhd Impacting the U.S. Workforce

Akili, Inc. Announces CEO Changes

Akili, Inc. Announces CEO Changes

Akili Releases EndeavorOTC on Android Devices, Expanding Treatment Access for Millions of Adults with Adhd

Price target decreased by 25% to US$3.00

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 14%

Consensus revenue estimates decrease by 44%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akili Releases EndeavorOTC Video Game Treatment to Improve Attention in Adults with Adad

Akili, Inc. to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with Adolescents At 2023

Consensus revenue estimates increase by 32%, EPS downgraded

Price target decreased by 8.3% to US$3.44

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 26%, EPS upgraded

Full year 2022 earnings released: US$0.10 loss per share (vs US$106 loss in FY 2021)

Akili, Inc. announces Pivotal Trial of Endeavorrx in Adolescents with Adhd Shows Robust Improvements in Attention and Broader Clinical Outcomes

Akili, Inc. Announces the Appointment of Scott Kollins, Ph.D., as Chief Medical Officer, Effective December 1, 2022

Consensus forecasts updated

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: US$35.91 (vs US$15.61 loss in 3Q 2021)

Akili, Inc. Announces Board Changes

Akili surges 21% as Singapore investment firms take joint stake

Second quarter 2022 earnings released

No independent directors

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Akili, Inc. Samenvatting

17.5x

-0.7x

Inkomsten en omzet